Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma A/S (ASND)
NASDAQ:ASND
ASND Stock Chart & Stats
$239.22
-$0.55(-0.40%)
At close: 4:00 PM EST
$239.22
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$124.06 - $242.44
Previous CloseN/A
Volume129.18K
Average Volume (3M)755.31K
Market Cap
$14.86B
Enterprise Value$12.97B
Total Cash (Recent Filing)$615.78M
Total Debt (Recent Filing)$871.41M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
May 27, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding61,977,410
10 Day Avg. Volume771,921
30 Day Avg. Volume755,308
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue18.07
Enterprise Value/Gross Profit20.95
Enterprise Value/Ebitda-160.76
Forecast
1Y Price Target
$289.50Price Target Upside21.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)4.73
Revenue Forecast (FY)$1.39B
Bulls Say, Bears Say
Bulls Say
Combination Therapy EfficacyClinical data showing TransCon CNP plus growth hormone increases linear growth and improves body proportionality supports the combo as a meaningful treatment option for patients needing additional height gains.
Regulatory And Commercial ReadinessCompletion of an End-of-Phase meeting and a planned pivotal study, combined with an established commercial infrastructure, supports regulatory progress and prepares the company for an efficient product launch.
Safety ProfileA more physiological mechanism of action for TransCon CNP may lead to improved long-term safety compared with receptor inhibitors, enhancing physician confidence in the therapy.
Bears Say
Clinical Durability ConcernsKey opinion leaders questioning whether adding growth hormone provides a durable long-term benefit raises doubts about the long-term value of the combination approach.
Competitive Pressure From Oral TherapiesOral competitors with convenient dosing may attract patients who prefer to avoid injections, creating notable competitive pressure on injectable therapies like TransCon CNP.
Label And Perceived Value LimitationsA product label that documents only increased linear growth without other validated clinical benefits could limit perceived value among payers and clinicians and constrain adoption.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $124.06 and its highest was $242.44 in the past 12 months.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market cap is $14.86B.
When is Ascendis Pharma A/S’s upcoming earnings report date?
Ascendis Pharma A/S’s upcoming earnings report date is May 27, 2026 which is in 84 days.
How were Ascendis Pharma A/S’s earnings last quarter?
Ascendis Pharma A/S released its earnings results on Feb 11, 2026. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.093 by -$0.547.
Is Ascendis Pharma A/S overvalued?
According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued.
Does Ascendis Pharma A/S pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
What is Ascendis Pharma A/S’s EPS estimate?
Ascendis Pharma A/S’s EPS estimate is 0.39.
How many shares outstanding does Ascendis Pharma A/S have?
Ascendis Pharma A/S has 61,977,410 shares outstanding.
What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
Ascendis Pharma A/S reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.093. Following the earnings report the stock price went down -1.531%.
Which hedge fund is a major shareholder of Ascendis Pharma A/S?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$289.50 (21.02% Upside)
$289.50 (21.02% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 6.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.25%
Trailing 12-Months
Company Description
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive and growth-focused: management reported strong commercial execution (notably Yorvipath and Skytrofa), meaningful pipeline and regulatory progress (including imminent PDUFA for TransCon CNP and compelling combination data), and a strengthened cash position with an ambitious operating cash flow outlook for 2026. Key headwinds include high operating expenses (which slightly exceeded 2025 revenue), a substantial noncash finance remeasurement loss, currency-driven revenue headwinds, and remaining access / penetration and competitive uncertainties. Taken together the positives around revenue momentum, pipeline advancement, partnerships, and a stronger financial base outweigh the near-term financial and market-access challenges.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$289.50
▲(21.02% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
Currently, No data available
---